The Hon Greg Hunt MP, Minister for Health recently announced that TEVA Pharma Australia’s new treatment for the prevention of chronic migraine in adults, AJOVY®, will be listed on the Pharmaceutical Benefits Scheme (PBS).
Such a listing will save chronic migraine sufferers thousands of dollars a year making treatment more affordable and accessible with the PBS helping to subsidise the cost of the prescriptions.
Minister Hunt indicated “It is estimated around 20 per cent of the population live with migraine or experience migraine attacks at some stage in their lives. Migraines often appear in childhood, adolescence or early adulthood, but affect the greatest number of people between 35 and 45 years of age who experience migraine attacks. Without PBS subsidy, around 10,000 Australians would pay around $6,700 per year for this new treatment.”
Benet Irish, General Manager, TEVA Pharma Australia, said, “The approval of AJOVY is an important step forward for the Australian migraine community and we congratulate the Government for providing Australians an additional treatment option. At TEVA, we believe that innovation does not end at scientific discovery. It extends to ensuring our treatments are accessible to the people who need it most. We are truly passionate and committed to improving health and creating better days for the migraine community now and in the future.”